The Medical Advisory Board of When Everyone Survives has been established to provide counsel and direction to the foundation's research efforts. It is a role that we see as being pivotal in maintaning the focus with which the foundation was created. A cure or cures for leukemia are closer now than ever in history. It is only through research and the funding it requires that those cures can be identified.
The Medical Advisory Board will determine the most relevant, productive and promising research initiatives that, in their opinion, can most benefit from the funding the foundation will be able to provide annually and provide the direction for distribution of those funds. When Everyone Survives is indebted to them and appreciative of their dedication to the cause and their willingness to serve in this capacity.
We feel very blessed to have individuals of their character providing us the direction we seek. We appreciate their expertise, their counsel, their generosity and their dedication in assisting us with finding the cure that will assure a day when everyone survives.
Meet our Medical Advisory Board
Chairman:
Edmund K. Waller, MD, PhD, FACP
Dr. Waller received his MD and PhD degrees from the Cornell Rockefeller program at Cornell University and his clinical training in Oncology from Stanford University Hospital. He has been on the Emory University School of Medicine faculty for the past 11 years serving as an associate professor and has served as Medical Director of the Bone Marrow and Stem Cell Transplant Center since 1999. Additionally, he has served as the Medical Director for Clinical Trials at the Winship Cancer Institute since 2005. His research interests are in optimizing the graft versus leukemia effect of allogeneic transplantation and in optimizing the safety of the transplant maneuver. He has an active basic science research laboratory and is active in enrolling patients on clinical trials that investigate new therapies for patients with leukemia, multiple myeloma, and lymphoma. He sees patients with leukemia, MDS, lymphoma and myeloma who are considering autologous or allogeneic transplantation in the management of their disease or patients who are candidates for clinical trials that investigate new therapies for these diseases.
Amelia Langston, MD
Dr. Langston has been a member of the Emory faculty since 1998, and is currently an Associate Professor of Hematology/Oncology. She graduated from Washington University School of Medicine in St Louis, did her Internal Medicine residency training at Duke University Medical Center and fellowship training at the University of Washington/Fred Hutchinson Cancer Research Center. Dr. Langston is the Medical Director and Section Chief of the Bone Marrow Transplant Program, and she is also an active researcher in the Leukemia Program with a primary interest in acute myelogenous leukemia and myelodysplastic syndromes. Her other research interests include novel approaches for allogeneic transplantation, prevention and therapy of graft-versus-host disease, and prevention and management of opportunistic infections in immunocompromised patients.
Leon Bernal-Mizrachi, MD
Dr. Bernal-Mizrachi is an instructor of Hematology and Oncology in the Winship Cancer Institute at Emory University. Dr Bernal-Mizrachi's medical degree was obtained at the Valle University in Colombia, and his clinical Hematology/Oncology training was obtained at Washington University in St. Louis, MO. His postdoctoral training in molecular oncology was obtained at Washington University (Lee Ratner's Laboratory). Dr Bernal-Mizrachi's clinical and research interests focus on lymphomas and leukemias. His laboratory studies the molecular mechanism by which NF-kB produces lymphomagenesis, focusing on protein interactions and the identification of NF-kB dependent genes that contribute to pathophysiologic lymphoid formation. Dr.Bernal-Mizrachi's laboratory team includes Qyung Yang, MD and Joan Cain, MD. For further information and publication record: http://www.pharm.emory.edu/hfu/researchbernal.htm
Mary Jo Lechowicz, MD
Dr. Lechowicz received her B.A. from Hofstra University, Hemptead, New York. She earned her M.D. from the State University of New York in Syracuse and completed her internship, residency, and chief residency at Columbia Presbyterian Medical Center. She went on to complete a fellowship in oncology at the Sidney Kimmel Cancer Center at Johns Hopkins in Baltimore, Maryland. Dr. Lechowicz joined the Winship Cancer Institute in July of 2003 and is an Associate Professor at the Emory University school of Medicine.
Her research interests focus on novel therapies for Hodgkin’s and Non-Hodgkin’s Lymphomas specifically cutaneous and peripheral T-cell lymphomas. Dr. Lechowicz is the primary investigator for 14 trials at Emory University with regard to improvement of care in non-Hodgkin’s lymphomas, particularly related to transplantation and diffused B-cell lymphomas; cutaneous and peripheral lymphomas; T-cell lymphomas; and HIV and lymphoma care.
Dr. Lechowicz was editor for the American Society of Hematology Daily News in 2010, and she has served on multiple committees including: the United States Cutaneous Lymphoma Consortium, American Society of Hematology, the ethics committee at Columbia Presbyterian Medical Center at Johns Hopkins, the ECOG Core Committee, and the Lymphoma Research Foundation’s Lymphoma Awareness Multicultural Population Advisory Committee.
|
